| Literature DB >> 34926017 |
Helin Şahintürk1, Beyza Meltem Yurtsever1, Özgür Ersoy2, Seda Kibaroğlu3, Pınar Zeyneloğlu1.
Abstract
Introduction Neurologic complications after transplantation surgery are major causes of morbidity, and the incidence of neurologic complications among heart transplant recipients varies from 7% to 81%. In our study, we aimed to determine the incidence, etiologies, and risk factors of neurologic complications among patients readmitted to the intensive care unit (ICU) after heart transplantation. Method In this retrospective cohort study, the medical records of all patients who underwent cardiac transplantation from February 2003 to July 2019 were reviewed, and those admitted to the ICU due to neurologic complications during the early and late postoperative period were evaluated. The patients were divided into two groups based on the development of neurologic complications to compare demographic and other characteristics. Results A total of 130 heart transplant recipients were analyzed. We excluded 33 patients from the study because they either had neurologic complications or died postoperatively without discharge from the intensive care unit. The mean age of the cohort was 35.4 ± 18.5 years, and 74 (76.3%) were male. Out of those 97 heart transplant recipients, 22 (22.7%) developed neurologic complications. Five patients (22.7% ) were admitted to the ICU in the first month, six patients (27.3%) were admitted to the ICU between one and six months, and 11 patients (50%) were admitted to the ICU six months after transplantation due to neurologic complications. The most common diagnosis was posterior reversible encephalopathy syndrome (PRES) (n = 6, 27.3%). The other diagnoses were calcineurin inhibitor toxicity (n = 5, 22.7%), intracranial hemorrhage (n = 3, 13.6%), seizures (n = 2, 9.2%), stroke (n = 2, 9.2%), femoral neuropathy (n = 1, 4.5%), myopathy (n = 1, 4.5%), phrenic nerve damage (n = 1, 4.5%), and cerebral abscess (n = 1, 4.5%). The rate of neurologic complications was higher in males when compared with females (p = 0.03). Both groups were similar in terms of the etiologies of cardiac failure, coexisting disease, and anticoagulant and immunosuppressive usage. The requirement for mechanical ventilation, renal replacement therapy, and the incidence of acute kidney injury were similar in both groups (p > 0.05). The incidence of sepsis was significantly higher in patients with neurologic complications (n = 8, 36.4%, versus n = 5, 6.7%; p < 0.001). The mean length of hospital stay was significantly higher in patients with neurologic complications (21.4 ± 15.8 versus 11.1 ± 13.3 days, p = 0.01). The risk of developing neurologic complications is 3.036 times higher in males, and this is statistically significant (odds ratio (OR), 3.036; 95% confidence interval (CI), 1.078-8.444; p = 0.036). Conclusion Our results suggest that neurologic complications develop in 22.7% of heart transplant recipients admitted to the ICU, and half of them are seen after six months postoperatively. PRES was the most frequent (27.3%) neurologic complication. The risk of neurologic complications is three times higher for males. The mean length of hospital stay and incidence of sepsis were significantly higher in heart transplant recipients who developed neurologic complications.Entities:
Keywords: heart transplantation; icu; intensive care unit; neurologic complications; transplantation
Year: 2021 PMID: 34926017 PMCID: PMC8654072 DOI: 10.7759/cureus.19425
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Demographic characteristics and main diagnosis of the study population [mean ± SD or n (%)]
| n = 97 (%) | |
| Age (years) | 35.4 ± 18.5 |
| Male | 74 (76.3%) |
| Diagnosis | |
| Dilated cardiomyopathy | 59 (60.8%) |
| Restrictive cardiomyopathy | 12 (12.4%) |
| Ischemic cardiomyopathy | 15 (15.5%) |
| Myocarditis | 3 (3.1%) |
| Congenital heart disease | 7 (7.2%) |
| Arrhythmogenic right ventricular cardiomyopathy | 1 (1%) |
Timing of neurologic complications
| Postoperative | n (22) | % (100%) |
| One month | 5 | 22.7 |
| One to six months | 6 | 27.3 |
| >6 months | 11 | 50 |
Neurologic complications
PRES: posterior reversible encephalopathy syndrome
| n (22) | % (100%) | |
| PRES | 6 | 27.3 |
| Calcineurin inhibitor toxicity | 5 | 22.7 |
| Hemorrhage | 3 | 13.6 |
| Seizures | 2 | 9.2 |
| Stroke | 2 | 9.2 |
| Femoral neuropathy | 1 | 4.5 |
| Phrenic nerve damage | 1 | 4.5 |
| Myopathy | 1 | 4.5 |
| Brain abscess | 1 | 4.5 |
Comparison of the two groups in terms of demographics, etiologies, coexisting disease, and immunosuppressive drugs [mean ± SD or n (%)]
*p value of Fisher’s exact test
**p value < 0.05
NC: neurologic complications, ICMP: ischemic cardiomyopathy, DCMP: dilated cardiomyopathy, RCMP: restrictive cardiomyopathy, ARVC: arrhythmogenic right ventricular cardiomyopathy, HTN: hypertension, DM: diabetes mellitus
| NC (-) | NC (+) | p | ||
| Age | ≤18 | 18 (24) | 6 (27.3) | 0.754 |
| >18 | 57 (76) | 16 (72.7) | ||
| Gender | Male | 61 (81.3) | 13 (59.1) | 0.031** |
| Female | 14 (18.7) | 9 (40.9) | ||
| Etiologies | ICMP | 14 (18.7) | 1 (4.5) | 0.086* |
| DCMP | 40 (53.3) | 19 (86.5) | ||
| RCMP | 11 (14.7) | 1 (4.5) | ||
| Myocarditis | 2 (2.7) | 1 (4.5) | ||
| Congenital | 7 (9.3) | 0 (0) | ||
| ARVC | 1 (1.3) | 0 (0) | ||
| Coexisting disease | HTN | 4 (5.3 ) | 2 (9.1) | 0.222* |
| Pulmonary HTN | 5 (6.7) | 1 (4.5) | ||
| DM | 1 (1.3) | 1 (4.5) | ||
| Cardiac failure | 55 (73.5) | 12 (54.5) | ||
| Chronic renal failure | 1 (1.3) | 0 (0) | ||
| Malignancy | 1 (1.3) | 1 (4.5) | ||
| Arrhythmia | 4 (5.3) | 1 (4.5) | ||
| Others | 4 (5.3) | 4 (18.2) | ||
| Immunosuppressive agent | Tacrolimus | 59 (78.7) | 17 (77.3) | 0.788* |
| Cyrolimus | 13 (17.3) | 5 (22.7) | ||
| Cyclosporine | 3 (4) | 0 (0) |
Comparison between the two groups in terms of outcomes [mean ± SD or n (%)]
*p value of Fisher’s exact test
**p value < 0.05
NC: neurologic complications, AKI: acute kidney injury, RRT: renal replacement therapy, MV: mechanical ventilation, ICU: intensive care unit
| NC (-) | NC (+) | p | |
| Sepsis | 5 (6.7%) | 8 (36.4%) | <0.001** |
| AKI | 19 (25.3%) | 4 (18.2%) | 0.488 |
| RRT requirement | 17 (22.7%) | 3 (13.6%) | 0.357 |
| Need for intubation | 33 (44%) | 10 (45.5%) | 0.904 |
| Need for MV | 34 (45.3%) | 11 (50%) | 0.700 |
| Duration of MV (hours) | 7 ± 10.24 | 4.90 ± 5.26 | 0.714 |
| Tracheostomy | 7 (9.3%) | 1 (4.5%) | 0.473 |
| Organ deficiency | 20 (27%) | 7 (31.8%) | 0.661 |
| Use of vasopressors | 30 (40%) | 8 (36.4%) | 0.759 |
| Neurologic deficit | 0 (0%) | 1 (4.5%) | 0.227* |
| Length of ICU stay (days) | 9.08 ± 12.28 | 8.76 ± 8.72 | 0.970 |
| Length of hospital stay (days) | 11.08 ± 13.25 | 21.40 ± 15.77 | 0.015** |
| Mortality (30 days) | 31 (41.3%) | 5 (27.7%) | 0.112 |
| ICU mortality | 33 (44%) | 7 (31.8%) | 0.307 |
| Hospital mortality |
Univariate logistic regression results
**p value < 0.05
B: regression coefficient, Exp (B): odds ratio, S. error: standard error of regression coefficient (B), Min: minimum, Max: maximum, CI: confidence interval
| Variables | B | S. error | Exp (B) | 95% CI | p | |
| Min | Max | |||||
| Gender (male) | 1.104 | 0.525 | 3.036 | 1.078 | 8.444 | 0.036** |